Title

1

4

5

7

8

13

14

15

25

26

- 2 Increasing prevalence of HIV-1 Transmitted Drug Resistance in Portugal: implications for first
- 3 line treatment recommendations

Running title

6 Increasing prevalence of HIV-1 TDR in Portugal

- **Authors**
- 9 Marta Pingarilho¹, Victor Pimentel¹, Isabel Diogo², Sandra Fernandes², Mafalda Miranda¹,
- 10 Andrea Pineda-Pena¹, Pieter Libin^{3,4}, Kristof Theys³, M. Rosário O. Martins¹, Anne-Mieke
- 11 Vandamme^{1,3}, Ricardo Camacho³, Perpétua Gomes^{2,5}, Ana Abecasis¹, on behalf of the
- 12 Portuguese HIV-1 Resistance Study Group&

Affiliations

- 16 Global Health and Tropical Medicine (GHTM), Instituto de Higiene e Medicina
- 17 Tropical/Universidade Nova de Lisboa (IHMT/UNL), Lisboa, Portugal
- 18 Laboratório de Biologia Molecular (LMCBM, SPC, CHLO-HEM), Lisboa, Portugal 2-
- 19 KU Leuven, Clinical and Epidemiological Virology, Department of Microbiology and 3-
- 20 Immunology, Rega Institute for Medical Research, Belgium.
- 21 Artificial Intelligence lab, Department of computer science, Vrije Universiteit Brussel, 4-
- 22 Brussels, Belgium
- 23 Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Instituto Superior de 5-
- 24 Ciências da Saúde Egas Moniz, Caparica, Portugal
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

28 Authors' e-mail addresses 29 MP- martapingarilho@ihmt.unl.pt 30 VP- victor.pimentel@ihmt.unl.pt 31 ID- ifmadeira@chlo.min-saude.pt 32 SF- smfernandes@chlo.min-saude.pt 33 MM- a21000919@ihmt.unl.pt 34 AP- andreapinedap@gmail.com 35 PL- pieter.libin@vub.ac.be 36 KT- kristof.theys@kuleuven.be 37 MRM- mrfom@ihmt.unl.pt 38 AV- annemie.vandamme@kuleuven.be 39 RC- ricardojorge.camacho@kuleuven.be 40 PG- pcrsilva@chlo.min-saude.pt 41 AA- ana.abecasis@ihmt.unl.pt 42 43 § Corresponding author 44 Ana Barroso Abecasis (AA) 45 Global Health and tropical Medicine (GHTM), Institute of Hygiene and Tropical medicine (IHMT) 46 New university of Lisbon 47 Lisbon, Portugal, 1300-028 48 E mail: ana.abecasis@ihmt.unl.pt 49 Contact no: +351 213 652 600 50 51 & Membership of the Portuguese HIV-1 Resistance Study Group is provided in the 52 Acknowledgements 53 54

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

Keywords HIV-1; Temporal trends; Transmitted drug resistance; Acquired drug resistance; Portugal **Abstract** Background: Treatment for all recommendations has allowed access to antiretroviral (ARV) treatment to an increasing number of patients. This minimizes transmission of infection but can potentiate the risk for development of transmitted drug resistance (TDR) and acquired drug resistance (ADR). Objective: To study the trends of TDR and ADR in patients followed in Portuguese hospitals between 2001 and 2017. Method: 11911 patients of the Portuguese REGA database were included. TDR was defined as the presence of one or more surveillance drug resistance mutations according to the WHO surveillance list. Phenotypic resistance to ARV was evaluated with Standford HIVdb v7.0. Patterns of TDR, ADR and prevalence of mutations over time were analysed with logistic regression. Results: The prevalence of TDR increased from 7.9% in 2003 to 13.1% in 2017 (pfor-trend<0.001). This was due to a significant increase of both resistance mutations to nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleotide reverse transcriptase inhibitors (NNRTIs) from 5.6% to 6.7% (p_{for-trend}=0.002) and 2.9% to 8.9% (p_{for-trend}<0.001), respectively. TDR to Protease Inhibitors decreased from 4.0% in 2003 to 2.2 in 2017 (p_{for-trend} =0.985). Paradoxically, the prevalence of ADR declined from 86.6% in 2001 to 51.0% in 2017 (p_{for-trend}<0.001) caused by a declining drug resistance to all ARV classes (p_{for-trend}<0.001). Conclusions: While ADR is declining since 2001, TDR has been increasing, reaching a value of 13.1% by the end of 2017. It is urgent to develop public health programs to monitor levels and patterns of TDR in newly diagnosed patients.

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

Introduction In 2014, the WHO proposed the 90-90-90, an ambitious treatment target to help end the AIDS pandemic. In Portugal, a national report estimated that in 2017, 38.959 people were living with HIV, with an incidence of 8.6 cases per 100,000 habitants in 2017, one of the highest in Europe. Of these, 91.7% of patients were diagnosed, 86.8% of the diagnosed were receiving antiretroviral treatment (ART) and 90.3% of the treated patients (TP) were virally suppressed [1]. In summary, Portugal is very close to achieving the 90-90-90 objectives, lacking only a small proportion of patients under treatment. A major threat to achieve the 90-90-90 target is ARV drug resistance. While ART largely decreases HIV-related morbidity and mortality, improves quality of life of HIV-1 infected patients and reduces the risk of onward transmission [2–4], its scale up can potentiate the risk for development of ARV drug resistance. International guidelines consistently recommend that newly diagnosed individuals should be tested for ARV drug resistance to detect potential transmitted drug resistance (TDR) and guide the selection of ART regimens [5,6]. This procedure minimizes the risk of experiencing virologic failure after starting ART due to the selection of resistant HIV isolates, resulting in acquired drug resistance (ADR). Active surveillance of TDR and ADR is crucial to understand factors involved in the transmission of HIV-1 drug resistance and, also, to help to design effective ART treatment guidelines in different epidemic settings. Drug resistance evolves dynamically and therefore it is extremely important to monitor temporal trends of TDR and ADR. In this study, we aim to describe the temporal trends of TDR and ADR between 2001 and 2017, as well as the single mutations involved in that resistance and to identify predictors of TDR among HIV-1 infected patients treated in Portuguese hospitals.

Methods

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

Study population The protocol was in accordance with the declaration of Helsinki and approved by the Ethical Committee of Centro Hospitalar de Lisboa Ocidental (108/CES-2014). The Portuguese HIV-1 resistance database contains anonymized patients' information, including demographic, clinical and genotype resistance data from patients followed in 22 hospitals located around the country and collected between May 2001 and December 2017. All patient data collected in RegaDB [7] were generated during routine clinical care. Individuals aged 18 years or over and which had a HIV-1 drug resistance test performed were included. Patients' viral sequences were categorized into drug naïve (DN) and treated patients (TP). The CD4 cell count and HIV-1 viral load measured closest to the date of the resistance test were included in the analysis. Drug resistance analyses and subtyping The genomic data included protease and reverse transcriptase sequences obtained through population sequencing completed in Laboratório de Biologia Molecular do Hospital de Egas Moniz, CHLO. TDR was defined as the presence of one or more surveillance drug resistance mutations (SDRM) according to the WHO 2009 surveillance list [8]. Nucleotide sequences were submitted to the Calibrated Population Resistance tool - HIV drug resistance database version 6.0. Phenotypic resistance to ARV drugs was evaluated using the Standford HIVdb v8.4. Using this algorithm, ADR mutations were also identified. HIV-1 subtypes and circulating recombinant forms (CRF) were determined as previously described [9,10]. Statistical analysis Proportions and confidence intervals for proportions were calculated using 95% Wilson confidence interval for binomially distributed data. The differences between the prevalence of resistance in naïve and treated patients were analyzed using the Mann-Whitney-U-test and the X² tests. Logistic regression was used to examine the association between demographic and clinical

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

factors and the prevalence and the impact of SDRMs and to analyse trends over time. Results were considered statistically significant when p-values were below 0.05. All analyses were conducted in SPSS Statistic version 25 software and R3.5.1. More information in Supplementary File 1. **Results Population** Of 12792 patients, 11912 (93.1%) patients presented viral sequences. More than a half (7310, 61.4%) were from drug naïve and 3848 (32.3%) from treated patients. ART status was not available for 754 (6.3%) patients. Population characteristics are described in text and in Table A in Supplementary File 1. Transmitted HIV drug resistance (TDR) Overall, the prevalence of TDR between 2001 and 2017 was 9.4%. Non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations were detected in 5.0% of drug-naive patients, 4.0% for nucleoside reverse transcriptase inhibitor (NRTI) and 2.8% for protease inhibitors (PI). 8.5% presented single class resistance, 0.7% dual class resistance and 0.2% triple class resistance (Table 1).


Table 1- Proportion of transmitted drug resistance between 2003 and 2017 and of acquired drug resistance between 2001 and 2017


Transmitted drug resistance (TDR)	n (%)	95% CI	OR (95% CI)	p for trend			
Prot/RT sequence from naïve patients	Proportion of DRMs						
Total	7310 (100.0%)						
Any DRMs	690 (9.4%)	8.8-10.1	1.003 (1.002-1.005)	<0.001			
NRTI resistance	289 (4.0%)	3.5-4.4	1.002 (1.001-1.003)	0.002			
NNRTI resistance	367 (5.0%)	4.5-5.5	1.003 (1.001-1.004)	<0.001			
PI resistance	206 (2.8%)	2.5-3.2	1.000 (0.999-1.001)	0.985			
Single class resistance	625 (8.5%)	7.9-9.2	1.004 (1.002-1.005)	<0.001			
Dual class resistance	48 (0.7%)	0.5-0.9	1.000 (0.999-1.000)	0.067			
PI + NRTI resistance	47 (0.6%)	0.5- 0.8	1.000 (0.999-1.000)	0.100			
PI + NNRTI resistance	35 (0.5%)	0.3-0.7	1.000 (0.999-1.000)	0.777			
NRTI+NNRTI resistance	107 (1.5%)	1.2-1.8	1.002 (1.001-1.002)	<0.001			
Triple class resistance	17 (0.2%)	0.1-0.4	1.000 (0.999-1.000)	0.668			

Acquired drug resistance (ADR)	n (%)	95% CI	OR (95% CI)	p for trend			
Prot/RT sequence from treated patients	Proportion of DRMs						
Total	3848 (100.0%)						
Any DRMs	2657 (69.0%)	67.6-70.5	0.970 (0.967-0.973)	<0.001			
NRTI resistance	2225 (57.8%)	56.2-59.4	0.964 (0.961-0.968)	<0.001			
NNRTI resistance	1763 (45.8%)	44.2-47.4	0.988 (0.985-0.992)	<0.001			
PI resistance	909 (23.6%)	22.3-25.0	0.972 (0.969-0.975)	<0.001			
Single class resistance	1247 (32.4%)	31.0-33.9	0.987 (0.984-0.991)	<0.001			
Dual class resistance	1029 (26.7%)	25.4-28.2	0.995 (0.992-0.998)	0.001			
PI + NRTI resistance	830 (21.6%)	20.3- 22.9	0.972 (0.969-0.975)	<0.001			
PI + NNRTI resistance	405 (10.5%)	9.6- 11.5	0.987 (0.985-0.990)	<0.001			
NRTI+NNRTI resistance	1386 (36.0%)	34.5-37.5	0.983 (0.980-0.986)	<0.001			
Triple class resistance	381 (9.9%)	9.0-10.9	0.988 (0.986-0.990)	<0.001			

Trends for TDR were determined only between the years 2003 and 2017, since between 2001 and 2002 the number of patients tested for ARV drug resistance was not large enough to allow for robustness in statistical analyses.

TDR presented a significantly increasing trend from 7.9% in 2003 to 13.1% in 2017 (p_{fortrend}<0.001). This trend is steeper in the last four years analysed (2014 to 2017) (p_{fortrend}=0.008). Since treatment for all recommendations were implemented in Portugal in September 2015, trends between September 2015 and December 2017 was also analysed, but was not found to be statistically significant (p_{for-trend}=0.507) (Figure 1(A) and Table 1, and Table B in Supplementary File 1).





All rights reserved. No reuse allowed without permission.

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

Figure 1: Proportion of (A) transmitted drug resistance (TDR) in sequences from naïve patients between 2003 and 2017 and (B) of acquired drug resistance (ADR) in treated patients between 2001 and 2017 This increasing trend was significant for two drug classes: NRTIs (5.6% in 2003 to 6.7% in 2017, $p_{\text{for-trend}} = 0.002$) and NNRTIs (2.9% in 2003 to 8.9% in 2017, $p_{\text{for-trend}} < 0.001$). For PIs, on the other hand, there was an opposite trend for lower drug resistance levels in more recent years (4.0% in 2003 to 2.2% in 2017). However, it was not significant (p_{for-trend}= 0.985) (Figure 1 (A), Table 1). Single class mutations increased over time from 5.2% (2003) to 12.2% (2017) whereas double class and triple class slightly decreased overtime (p_{for-trend}<0.001 for single class; p_{for-trend}=0.067 for double class; p_{for-trend}=0.668). Double class resistance to NRTIs/NNRTIs combinations presented an increase between 2011 and 2017 (p_{for-trend}=0.0604), whereas resistance to combinations of NRTIs/PIs and NNRTIs/PIs just presented a slight increase in the last years (2014-2017) (p_{for-trend}=0.272, p_{for-trend}=0.072, respectively) (Table 1 and Tables B and C in Supplementary File 1). The most frequently detected mutations were K103NS (3.2%) conferring resistance to NNRTIs, followed by M41L (1.6%) and M184V/I mutation (1.3%) conferring resistance to NRTIs and L90M (1.2%) conferring resistance to PIs (Supplementary Figure 1(A)). Acquired HIV drug resistance (ADR) ADR prevalence was 69.0%. NRTIs resistance mutations were predominantly identified (57.8%), followed by NNRTIs (45.8%) and PIs (23.6%). 32.4% presented single class resistance, 26.7% dual class resistance and 9.9% triple class resistance (Table 1). Overall, ADR decreased over time from 86.6 to 50.9 between 2001 and 2017 (p_{for-trend}<0.001) and between September 2015 and December 2017 (p_{for-trend}=0.836). Resistance to all drug classes presented declining trends over time (2001-2017): resistance to NRTIs dropped from 80.8% to All rights reserved. No reuse allowed without permission.

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

33.3% (p_{for-trend}<0.001); to NNRTIs from 46.4% to 40.2% (p_{for-trend}<0.001) and to PIs from 52.7% to 10.8% (p_{for trend}<0.001) (Figure 1(B) and Table 1, and Table B in Supplementary File 1). For single, double and triple class, significant declining trends were also observed: p_{for-trend}<0.001 for single class; pfor-trend=0.001 for double class and; pfor trend<0.001 for triple class); as well as for combinations of antiretroviral classes. NRTIs/NNRTIs combination decreased from 41.1% to 24.5%, NRTIs/PIs decreased from 51.3% to 8.8% and NNRTIs/PIs decreased from 23.2% to 6.9% between 2001 and 2017 (pfor-trend<0.001; pfor-trend<0.001 and pfor-trend<0.001 for NRTIs/NNRTIs, NRTIs/PIs and NNRTIs/PIs, respectively) (Table 1 and Table C in Supplementary File 1). The most prevalent mutations conferring resistance to NRTIs in treated patients, were M184IV (45.3%) and TAMs, such as T215YF (17.4%)) and M41L (16.0%). K103NS (26.0%) and L90M (11.3%) were the most prevalent mutations conferring resistance to NNRTIs and to PIs, respectively (Supplementary Figure 1 (B)). Trends for frequencies of specific drug resistance mutations were also analysed between 2001 and 2017 when mutations had a prevalence greater than 0.5% for drug-naive patients and 5.0% for treated patients. Among drug-naïve patients, although none of the mutations presented a statistically significant trend, we observed an increasing trend for M184V in the last years (Figure 3). For treated patients, on the other hand, PI resistance mutations M46IL, I54VLMTAS, V82ATSF and L90M presented statistically significant declining trends over time (pfor-trend <0.001). The same was observed for all mutations analysed for NRTIs regimens (pfor-trend <0.001) (Table D in Supplementary File) Drug susceptibility According to the HIVdb Standford database algorithm, 6.6% of DN patients (7310) presented high-level resistance to at least one drug. 5.4% of those have high-level resistance to a drug recommended for first line treatment. NNRTIs presented the highest level of high-level resistance (4.9%), with nevirapine (NVP) having the highest proportion of high-level resistance (4.7%),

followed by efavirenz (EFV) with 4.0% of high-level resistance. High-level resistance to NRTIs was 1.7%, with emtricitabine (FTC) and lamivudine (3TC) presenting the highest level (1.3%). High-level resistance to PIs was 1.8%, with atazanavir (ATV) presenting 0.3% of high-level resistance (Figure 2 (A)).

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247




Figure 2: Predicted phenotypic resistance (Standford scores) for antiretroviral drugs currently recommended as first line therapy in Portugal (A) for drug-naives patients (2003-2017) and (B) for treated patients (2003-2017). Scores of low-level (score 2 and 3), intermediate level (score 4) or high-level (score 5) resistance were used to predict phenotypic resistance. Abbreviations: NRTIs, Nucleoside reverse transcriptase inhibitors; NNRTIs, Non-nucleoside reverse transcriptase inhibitors; PIs, Protease inhibitors; FTC, Emtricitabine; TDF, Tenofovir; 3TC, Lamivudine; ABC, Abacavir; EVF, Efavirenz; RPV, Rilpivirine; DRV/r, Darunavir; LPV/r, Lopinavir; ATV/r, Atazanavir

Of 3848 treated patients, (64.0%) presented high-level of resistance to at least one ARV drug class, however considering only the drugs actually used as first line therapy the resistance decreased to 62.1%. For these patients, high-level resistance to NRTIs was the highest (54.4%) with high-level resistance to FTC and 3TC presenting the highest values (45.3%). 40.5% of patients presented high-level resistance to NNRTIs, with 40.1% presenting high-level resistance

to NVP and 35% to EFV. High-level resistance to PIs was 19.9%, with ATV presented the highest value (9.6%) (Figure 2 (B)).

Predictors of TDR

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

The factors significantly associated with TDR in the univariate model was being infected with subtype B (as compared to non-B subtypes grouped together) and the levels of logVL, while gender presented borderline significance. Although not reaching conventional statistical significance (p<0.05), male gender was associated with higher levels of TDR. It was also observed that being infected with subtype B and logVL above 5.1 presented statistical significance in relation to NRTIs drug resistance; being male, being from sub-Saharan Africa region, being infected with subtype B and logVL above 5.1 presented statistical significance related with PIs drug resistance and in relation to NNRTIs drug resistance logVL above 5.1 was significantly associated (Table E in Supplementary File 1). Multivariate analysis indicated statistically significant values of any TDR and NRTIs drug resistance for individuals infected with subtype B compared with non-B and presenting logVL higher than 5.1 (Table 2). We further observed that patients with a logVL above 5.1 presented lower levels of K103NS and L90M mutations (p=0.023 and p=0.008, respectively); while patients with a logVL above 4.1 presented lower levels of M184V (p=0.000) (Table 3).

Table 2- Multiple regression analysis of factors associated with HIV transmitted drug resistance

	Any TDR		NRTI TDR		NNRTI TDR		PI TDR	
Variable	OR (95%CI)	p	OR (95%CI)	p	OR (95%CI)	p	OR (95%CI)	р
Gender								
Female *								
Male	1.21 (0.95-1.55)	0.124	1.07 (0.73-1.59)	0.708	1.03 (0.75-1.40)	0.852	1.67 (1.07-2.94)	0.024
Age at diagnosis								
18-25*								
26-40	0.97 (0.69-1.36)	0.860	1.33 (0.72-2.44)	0.361	0.75 (0.49-1.15)	0.186	1.78 (0.91-3.50)	0.093
41-55	0.98 (0.68-1.40)	0.896	1.74 (0.63-3.07)	0.082	0.76 (0.48-1.21)	0.248	1.44 (0.70-2.94)	0.319

>56	1.15 (0.74-1.79)	0.520	1.40 (0.63-3.07) 0.405	1.20 (0.71-2.03) 0.498	2.02 (0.89-4.59)	0.091
Subtypes						
B*						
Non-B	0.74 (0.60-0.92)	0.006	0.45 (0.31-0.65) 0.000	1.19 (0.89-1.59) 0.240	0.65 (0.45-0.94)	0.021
Viral Load (log ₁₀ copies/ml)						
< 4.0*						
4.1 to 5.0	0.73 (0.56-0.96)	0.024	0.42 (0.28-0.63) 0.000	0.70 (0.49-1.00) 0.054	0.76 (0.49-1.19)	0.234
>5.1	0.66 (0.49-0.87)	0.004	0.38 (0.25-0.59) 0.000	0.65 (0.44-0.94) 0.023	0.50 (0.31-0.83)	0.007

Table 3- Association for the most prevalent drug-resistance mutation for each major drug class:

M184V, L90M, and K103N for NRTI, PI, and NNRTI with viral load

	M184V		K103NS		L90M	272
Variable	OR (95%CI)	p	OR (95%CI)	p	OR (95%CI)	^p 273
Viral Load (log10 copies/ml)						
< 4.0*						274
4.1 to 5.0	0.30 (0.17-0.54)	0.000	0.76 (0.51-1.12)	0.164	0.64 (0.35-1.16)	275
>5.1	0.15 (0.07-0.33)	0.000	0.62 (0.41-0.94)	0.023	0.40 (0.20-0.78)	$\frac{0.008}{276}$

* Reference category

268

269

270

271

277

278

279

280

281

282

283

284

285

286

287

Predictors of ADR

Univariate logistic regression analysis exploring predictors of acquired drug resistance is shown in Table F in Additional File 1. Being male, an age at diagnosis above 26 years old, being MSM (compared to being heterosexual), being born in Europe, being infected with subtype B and presenting logVL above 4.1 presented statistically significant results.

Multivariate analysis showed statistical significance for any ADR and NRTIs drug resistance for males, infected with subtype B and presenting viral loads above 4.1 (Table 4).

Table 4- Multiple regression analysis of factors associated with HIV acquired drug resistance

	Any ADR	NRTI ADR		NNRTI ADR	NNRTI ADR			
Variable	OR (95%CI)	p	OR (95%CI)	p	OR (95%CI)	p	OR (95%CI)	р
Gender								
Female *								
Male	1.44 (1.20-1.73)	0.000	1.40 (1.18-1.67)	0.000	1.15 (0.97-1.35)	0.112	1.66 (1.35-2.05)	0.000
Age at diagnosis								
18-25*								
26-40	1.12 (0.73-1.73)	0.602	1.13 (0.74-1.72)	0.565	0.85 (0.57-1.27)	0.420	1.71 (0.95-3.07)	0.072
41-55	1.07 (0.69-1.67)	0.764	1.11 (0.72-1.70)	0.626	0.83 (0.55-1.25)	0.375	1.76 (0.97-3.18)	0.062
>56	1.27 (0.76-2.12)	0.367	1.37 (0.84-2.24)	0.207	0.84 (0.53-1.35)	0.481	2.65 (1.40-5.02)	0.003
Subtypes								
B*								
Non-B	0.68 (0.57-0.80)	0.000	0.61 (0.52-0.72)	0.000	0.98 (0.84-1.14)	0.789	0.64 (0.54-0.77)	0.000
Viral Load (log ₁₀								
copies/ml)								
< 4.0*								
4.1 to 5.0	0.63 (0.52-0.76)	0.000	0.60 (0.50-0.71)	0.000	0.89 (0.75-1.05)	0.165	0.85 (0.70-1.03)	0.090
>5.1	0.34 (0.27-0.42)	0.000	0.29 (0.23-0.36)	0.000	0.69 (0.56-0.85)	0.001	0.50 (0.38-0.65)	0.000

Discussion

289

290

291

292

293

294

295

296

297

298

299

300

301

302

288

Our study showed that the estimated prevalence of TDR over time, among DN patients, increased between 2003 and 2017, and this increase was more pronounced between 2014 and 2017. While TDR to NRTIs and NNRTIs increased, TDR to PIs decreased me. We hypothesize that this increase could have different explanations. One hypothesis, that we have tested, is the implementation of the Treatment for All recommendations. The increasing trend for TDR is steeper since 2014, which could indicate a contribution of this public health measure to the increase of TDR. However, other factors could also be associated, namely the changing face of the epidemic, with an increasing proportion of MSMs among new diagnoses. This population is associated with faster onward transmission of HIV infection, which could potentiate transmission of TDR. Finally, the increasing mobility of populations and the presence in Portugal of a higher

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

number of migrants from countries where TDR has been increasing in the last years could also explain for this trend [11]. While we would expect that this should be seen in the proportion of TDR in non-B subtypes and we don't see it, we are exploring this in other independent analyses. Similarly to our study, a study of HIV drug resistance in a Canadian cohort showed an increase in TDR between 1996 and 2014, with a more prominent increase in the last years [12], which is consistent with our results. Some other studies, however, showed opposite results, with TDR prevalence declining or stabilizing over time [13–17]. A potential explanation for our discrepant results could be the origin of migrants living in Portugal, which come from Portuguese speaking Sub-Saharan African countries, where TDR has been increasing in the last years [18,19]. Strikingly, in the same time period (2001-2017) we found a significant declining trend in ADR, that span all drug classes. This trend has been consistently found in other studies. For example, in a multi-center European cohort (1997-2008) in Switzerland it was demonstrated that the majority of treated patients who initiated treatment in more recent years did not acquire drug resistance [20], as well as in another study in a large Canadian cohort (1996-2016) that showed that the prevalence of ADR has been declining for all drug categories [12]. Concordant results were also observed in an Italian cohort (2003-2012), in a German cohort (2001-2011), in Spain (1999-2005) and in Western Europe (1997-2008) [13,21-23]. Rocheleau et al (2017) have proposed that this declining trend of ADR is due to a combination of factors, that includes the increased efficacy of ARV regimens, readily accessible combination regimens and improved patient management [12]. The most frequently detected mutations in DN patients were K103NS conferring high-level resistance to NVP and EFV; and M41L, which reduces susceptibility to TDF and ABC when in combination with other NRTIs mutations. M184VI associated with high-level resistance to NRTIs also causes high-level reduced susceptibility to 3TC, FTC and ABC. L90M was the resistance mutation to PIs with highest prevalence. It causes reduced susceptibility to ATV and LPV when in combination with other PI-resistance mutations. While the transmission of K103NS is not that worrying given that NNRTIs are no longer recommended as first line treatment, M41L and M184IV have an impact to drugs recommended for first-line, so it is important to understand

All rights reserved. No reuse allowed without permission.

the impact of the transmission of these mutations and why its prevalence is increasing among DN patients (Figure 3). Furthermore, first line treatment recommendations are not used in many African countries, where regimens used for first line include drugs to which all these mutations cause resistance. It is also important to keep in mind that increasing mobility of populations can cause the spread and transmission of ARV drug resistance mutations in settings where other drugs are used.




Figure 3: Proportion of M184V, K103N and L90M mutations in (A) drug- naïve patients and (B) treated patients overtime between 2001 and 2017

For treated patients, the more prevalent mutations conferring resistance to NRTIs, were M184IV conferring high-level resistance to FTC and 3TC and also reduced susceptibility to ABC. K103NS was the most prevalent mutation conferring resistance to NNRTIs, specifically to NVP and EFV and L90M reducing susceptibility in combination with other PIs mutations, specifically to ATV and LPV. Importantly, overtime we observed an important reduction of specific PIs and NRTIs mutations, such as M46IL, L90M, M41L, L210W and M184IV. This could be associated with higher genetic barrier of boosted PIs and of dual NRTIs formulations (2014) [24].

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

According to the multivariate analysis performed in this study, the risk of TDR (and ADR) is significantly lower in patients infected with non-B subtypes compared to B subtype, as previously shown [25–28]. We hypothesize that this could be due to longer use of ARV therapy in developed countries, where this subtype is more prevalent, and to the circulation of this subtype in MSMs, where transmission chains are faster and therefore potentiate the transmission of TDR. However, there are features of the changing HIV-1 epidemic that could lead to an inversion of this pattern. The treatment for all, the increasing prevalence of non-B subtypes in developed countries and, particularly, the growing number of reports indicating transmission clusters of non-B subtypes in MSM could lead to an increase of TDR in non-B subtypes. Our multivariate analysis also showed that patients with TDR and ADR tended to present lower levels of VL at the time of resistance testing, which is consistent with the findings of the Swiss cohort [29], that found the same results in a population of DN patients and patients nonrespondent to first line regimens. It was also observed that lower VL of DN patients was associated with a higher level of patients presenting M184V and L90M mutation with statistical significance. Due to its high fitness cost [30], M184V quickly disappears after transmission in the absence of drug pressure [31]. These results are according with previous studies suggesting that higher viral load promote loss of mutations [29,30]. However, for K103NS no statistical association was found, which may be due to the differential fitness costs in relation to M184V, since K103NS are low-fitness-cost mutations that persist longer [32,33]. Other studies have shown that specific TDR mutations have an effect on the viral fitness that can have implications for its transmissibility [34,35]. We also found that the risk of ADR was significant higher in male patients, [13], in patients infected with subtype B and in patients with lower levels of VL at the time of resistance testing. ADR can be related to poor adherence, which has been shown to be a major determinant of virologic failure and emergence of drug resistant virus. Barriers to optimal adherence may originate from individual (biological, socio-cultural, behavioral), pharmacological, and societal factors; which make these findings more complex to interpret. Other studies also associated the development of ADR with levels of adherence in each era of therapy initiation [12,13].

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

Conclusion: In summary, our study showed that while ADR is declining since 2001, TDR has been steadily increasing, reaching a worrying value of 13.1% in 2017. While declining ADR seems to be caused mainly by the increasing efficacy of ARV therapy, TDR seems to be mainly driven by determinants of the virus such as viral subtype and fitness of the virus in the presence of particular mutations. Our results highlight that It is urgent to develop public health programs to monitor levels and patterns of TDR in newly diagnosed patients. **Conflict of interests' statement** The authors declare that they have no conflict of interests. Funding This study was supported by European Funds through grant 'Bio-Molecular and Epidemiological Surveillance of HIV Transmitted Drug Resistance, Hepatitis Co-Infections and Ongoing Transmission Patterns in Europe - BEST HOPE - (project funded through HIVERA: Harmonizing Integrating Vitalizing European Research on HIV/Aids, grant 249697); by FCT for funds to GHTM-UID/Multi/04413/2013; by the MigrantHIV project (financed by FCT: PTDC/DTP-EPI/7066/2014); by Gilead Génese HIVLatePresenters and by Characterization of drug-resistance TB and HIV, and associated socio-behavioral factors among migrants in Lisbon, Portugal project financed by GHTM-UID/Multi/04413/2013 **Authors' contributions** Conceptualization: MP and AA; Data curation: ID, SF, MP, AP and VP; Formal analysis: MP,

- 405 AP, MM, PL, KT and AA; Funding acquisition: AA; Investigation: MP, VP, PG, AV, RC and
- 406 PRSG; Methodology: MP, AP, VP and AA; Project administration: AA; Resources: PG, RC, AV
- 407 and PRSG; Supervision: AA; Validation: MP and MM; Writing – original draft: MP and AA;
- 408 Writing – review & editing: MP and AA.

Acknowledgements

- 412 We would like to thank the patients and all the members of the Portuguese HIV-1 Resistance
- 413 Study Group:

409

410

411

- 414 Fátima Gonçalves², Joaquim Cabanas², Ana Patrícia Carvalho², Inês Costa², Kamal Mansinho⁶,
- 415 Ana Cláudia Miranda⁶, Isabel Aldir⁶, Fernando Ventura⁶, Jaime Nina⁶, Fernando Borges⁶, Emília
- 416 Valadas⁷, Manuela Doroana⁷, Francisco Antunes⁷, Nuno Marques⁸, Maria João Aleixo⁸, Maria
- 417 João Águas⁸, Júlio Botas⁸, Teresa Branco⁹, Patrícia Pacheco⁹, Luís Duque⁹, José Vera¹⁰, Luís
- 418 Tavares¹⁰, Inês Vaz Pinto¹¹, José Poças¹², Joana Sá¹², António Diniz¹³, Margarida Serrado¹³, Ana
- 419 Mineiro¹³, Flora Gomes¹⁴, Cristina Guerreiro¹⁴, Carlos Santos¹⁵, Domitília Faria¹⁵, Paula
- 420 Fonseca¹⁵, Paula Proença¹⁶, Telo Faria¹⁷, Eugénio Teófilo¹⁸, Sofia Pinheiro¹⁸, Isabel Germano¹⁹,
- 421 Umbelina Caixas¹⁹, Margarida Bentes Jesus¹⁹, Nancy Faria²⁰, Ana Paula Reis²⁰, Graça Amaro²¹,
- 422 Fausto Roxo²¹, Ricardo Abreu²² and Isabel Neves²².
- 424 Affiliations:

423

- 425 6- Serviço de Doenças Infeciosas, Centro Hospitalar de Lisboa Ocidental, Hospital de Egas
- 426 Moniz, Lisboa, Portugal
- 427 7- Serviço de Infeciologia, Hospital de Santa Maria, Centro Hospitalar de Lisboa Norte, Lisboa,
- 428 Portugal
- 429 8- Serviço de Infeciologia, Hospital Garcia da Orta, Almada, Portugal
- 430 9- Serviço de Infeciologia, Hospital Dr. Fernando da Fonseca, Amadora, Portugal
- 431 10- Serviço de Medicina Interna, Centro Hospitalar do Barreiro-Montijo, Portugal
- 432 11- Unidade funcional VIH/SIDA, Hospital de Cascais, Cascais, Portugal

433 12- Serviço de Infeciologia, Centro Hospitalar de Setúbal, Setúbal, Portugal

- 434 13- Serviço de Pneumologia, Hospital Pulido Valente, Centro Hospitalar de Lisboa Norte, Lisboa,
- 435 Portugal
- 436 14- Serviço de Obstetrícia - Maternidade Alfredo da Costa, Centro Hospitalar de Lisboa
- 437 Central, Lisboa, Portugal
- 438 15- Serviço de Medicina Interna-Centro Hospitalar do Algarve, Hospital de Portimão, Portimão,
- 439 **Portugal**
- 440 16- Serviço de Infeciologia-Centro Hospitalar do Algarve, Hospital de Faro, Faro, Portugal
- 441 17- Unidade Local de Saúde do Baixo Alentejo, Hospital José Joaquim Fernandes, Beja, Portugal
- 442 18- Serviço de Infeciologia, Hospital de Santo António dos Capuchos, Centro Hospitalar de
- 443 Lisboa Central, Lisboa, Portugal
- 444 19- Serviço de Medicina 1.4, Centro Hospitalar de Lisboa Central, Hospital de São José, Lisboa,
- 445 Portugal

450

451

452

- 446 20- Serviço de Doenças Infectocontagiosas, Hospital Central do Funchal, Madeira, Portugal
- 447 21- Serviço de Doenças Infeciosas, Hospital Distrital de Santarém, Santarém, Portugal
- 448 22- Serviço de Infeciologia, Unidade de Local de Saúde de Matosinhos, Hospital Pedro Hispano,
- 449 Matosinhos, Portugal

References

- 453 Ministério da Saúde. Direção-Geral da Saúde. Infeção VIH e SIDA- Desafios e 1.
- 454 estratégias 2018. Portugal: DGS; 2018.
- 455 2. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality
- 456 among patients with advanced human immunodeficiency virus infection. HIV
- 457 Outpatient Study Investigators. N Engl J Med. 1998; 338(13):853–860.
- 458 Clavel F, Hance AJ. HIV drug resistance. N Engl J Med. 2004; 350(10):1023–1035. 3.

- 459 Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early 4.
- 460 antiretroviral therapy. N Engl J Med. 2011; 365(6):493-505.
- 461 Gazzard BG, Anderson J, Babiker A, et al. British HIV Association Guidelines for 5.
- 462 the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med.
- 463 **2008**; 9(8):563–608.
- 464 Hicks CB. Guideline watch. Antiretroviral drug resistance testing--updated 6.
- 465 guidelines from the IAS-USA. AIDS Clin Care. 2008; 20(8):64.
- 466 7. Libin P, Beheydt G, Deforche K, et al. RegaDB: community-driven data
- 467 management and analysis for infectious diseases. Bioinforma Oxf Engl. 2013;
- 468 29(11):1477–1480.
- 469 8. Bennett DE, Camacho RJ, Otelea D, et al. Drug Resistance Mutations for
- 470 Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update. PLOS ONE.
- 471 **2009**; 4(3):e4724.
- 472 9. Pineda-Peña A-C, Faria NR, Imbrechts S, et al. Automated subtyping of HIV-1
- 473 genetic sequences for clinical and surveillance purposes: performance evaluation of
- 474 the new REGA version 3 and seven other tools. Infect Genet Evol J Mol Epidemiol
- 475 Evol Genet Infect Dis. 2013; 19:337–348.
- 476 10. Struck D, Lawyer G, Ternes A-M, Schmit J-C, Bercoff DP. COMET: adaptive
- 477 context-based modeling for ultrafast HIV-1 subtype identification. Nucleic Acids
- 478 Res. 2014; 42(18):e144.
- 479 11. Developing a reporting system for the surveillance of HIV drug resistance in Europe
- [Internet]. Eur. Cent. Dis. Prev. Control. 2019 [cited 2019 Aug 9]. Available from: 480

- 481 http://ecdc.europa.eu/en/publications-data/developing-reporting-system-482 surveillance-hiv-drug-resistance-europe 483 12. Rocheleau G, Brumme CJ, Shoveller J, Lima VD, Harrigan PR. Longitudinal trends 484 of HIV drug resistance in a large Canadian cohort, 1996-2016. Clin Microbiol Infect 485 Off Publ Eur Soc Clin Microbiol Infect Dis. 2018; 24(2):185–191. 486 13. Schmidt D, Kollan C, Fätkenheuer G, et al. Estimating Trends in the Proportion of 487 Transmitted and Acquired HIV Drug Resistance in a Long Term Observational 488 Cohort in Germany. PLoS ONE [Internet]. 2014 [cited 2018 Oct 10]; 9(8). Available 489 from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4141736/ 490 14. Tostevin A, White E, Dunn D, et al. Recent trends and patterns in HIV-1 transmitted 491 drug resistance in the United Kingdom. HIV Med. 2017; 18(3):204–213. 492 15. Olson A, Bannert N, Sönnerborg A, et al. Temporal trends of transmitted HIV drug 493 resistance in a multinational seroconversion cohort. AIDS Lond Engl. 2018; 494 32(2):161–169. 495 16. UK Collaborative Group on HIV Drug Resistance, Dolling D, Sabin C, et al. Time 496 trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: 497 multicentre observational study. BMJ. 2012; 345:e5253. 498 17. Colafigli M, Torti C, Trecarichi EM, et al. Evolution of transmitted HIV-1 drug 499 resistance in HIV-1-infected patients in Italy from 2000 to 2010. Clin Microbiol 500 Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2012; 18(8):E299-304. 501 18. Pingarilho M, Pineda-Peña A, Gomes P, Libin P, Theys K, Abecasis A. Molecular
- 502 epidemiology of HIV infection in portuguese migrant population. Roma; 2018.

- 503 19. Rhee S-Y, Blanco JL, Jordan MR, et al. Geographic and Temporal Trends in the
- 504 Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug
- 505 Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. PLoS Med
- 506 [Internet]. 2015 2018 Oct 12]; cited 12(4). Available from:
- 507 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4388826/
- 508 20. Scherrer AU, Wyl V von, Yang W-L, et al. Emergence of Acquired HIV-1 Drug
- 509 Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis.
- 510 Clin Infect Dis. **2016**; 62(10):1310–1317.
- 511 21. Franzetti M, De Luca A, Ceccherini-Silberstein F, et al. Evolution of HIV-1
- 512 transmitted drug resistance in Italy in the 2007-2014 period: A weighted analysis. J
- 513 Clin Virol Off Publ Pan Am Soc Clin Virol. 2018; 106:49–52.
- 514 22. De Luca A, Dunn D, Zazzi M, et al. Declining prevalence of HIV-1 drug resistance
- 515 in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis.
- 516 **2013**; 207(8):1216–1220.
- 517 23. Mendoza C de, Garrido C, Corral A, et al. Changing rates and patterns of drug
- 518 resistance mutations in antiretroviral-experienced HIV-infected patients. AIDS Res
- 519 Hum Retroviruses. 2007; 23(7):879–885.
- 520 24. Franzetti M, Violin M, Antinori A, et al. Trends and correlates of HIV-1 resistance
- 521 among subjects failing an antiretroviral treatment over the 2003-2012 decade in
- 522 Italy. BMC Infect Dis. 2014; 14:398.
- 523 25. Descamps D, Chaix M-L, Montes B, et al. Increasing prevalence of transmitted drug
- 524 resistance mutations and non-B subtype circulation in antiretroviral-naive

- 525 chronically HIV-infected patients from 2001 to 2006/2007 in France. J Antimicrob
- 526 Chemother. **2010**; 65(12):2620–2627.
- 26. Riva C, Lai A, Caramma I, et al. Transmitted HIV Type 1 drug resistance and Non-527
- 528 B subtypes prevalence among seroconverters and newly diagnosed patients from
- 529 1992 to 2005 in Italy. AIDS Res Hum Retroviruses. **2010**; 26(1):41–49.
- 530 27. Bracciale L, Colafigli M, Zazzi M, et al. Prevalence of transmitted HIV-1 drug
- 531 resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors.
- 532 J Antimicrob Chemother. **2009**; 64(3):607–615.
- 533 28. Pineda-Peña A-C, Schrooten Y, Vinken L, et al. Trends and Predictors of
- 534 Transmitted Drug Resistance (TDR) and Clusters with TDR in a Local Belgian HIV-
- 535 1 Epidemic. PLOS ONE. 2014; 9(7):e101738.
- 536 29. Yang W-L, Kouyos R, Scherrer AU, et al. Assessing the Paradox Between
- 537 Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV
- 538 Cohort Study From 1998 to 2012. J Infect Dis. **2015**; 212(1):28–38.
- 539 30. Jain V, Sucupira MC, Bacchetti P, et al. Differential Persistence of Transmitted
- 540 HIV-1 Drug Resistance Mutation Classes. J Infect Dis. 2011; 203(8):1174–1181.
- 541 31. Paredes R, Sagar M, Marconi VC, et al. In Vivo Fitness Cost of the M184V Mutation
- 542 in Multidrug-Resistant Human Immunodeficiency Virus Type 1 in the Absence of
- 543 Lamivudine. J Virol. **2009**; 83(4):2038–2043.
- 544 32. Cong M, Heneine W, García-Lerma JG. The Fitness Cost of Mutations Associated
- 545 with Human Immunodeficiency Virus Type 1 Drug Resistance Is Modulated by
- 546 Mutational Interactions. J Virol. 2007; 81(6):3037–3041.

547 33. Armstrong KL, Lee T-H, Essex M. Replicative Fitness Costs of Nonnucleoside 548 Reverse Transcriptase Inhibitor Drug Resistance Mutations on HIV Subtype C v. 549 Antimicrob Agents Chemother. 2011; 55(5):2146–2153. 550 34. Winand R, Theys K, Eusébio M, et al. Assessing transmissibility of HIV-1 drug 551 resistance mutations from treated and from drug-naive individuals. AIDS Lond 552 Engl. **2015**; 29(15):2045–2052. 553 35. Wertheim JO, Kosakovsky Pond SL, Forgione LA, et al. Social and Genetic 554 Networks of HIV-1 Transmission in New York City. PLoS Pathog. 2017; 555 13(1):e1006000.

556

Supplementary files legend

Supplementary File 1- Text and Tables

This file contains an explained text with the methodology used to do the statistical analysis as well as the characterization of the Portuguese population included in this study.

Table A- Demographic and clinic patient characteristics, 2001-2017

Table B- Trends of transmitted drug resistance between 2006 and 2017, 2014 and 2017 and September 2014 and December 2017 and of acquired drug resistance between 2001 and 2017

Table C- Proportion of transmitted drug resistance and of acquired drug resistance for single, double and triple classes and for associations of drug classes between 2001 and 2017

Table D- Time trends of selected mutations with prevalence greater than 0.5% for drug-naïve patients and 5.0% for treated patients

Table E- Univariate analysis of factors associated with HIV transmitted drug resistance

Table F- Univariate analysis of factors associated with HIV acquired drug resistance

Supplementary Figure 1: Proportion of resistance mutations in sequences (A) drug naïve patients and (B) treated patients between 2001 and 2017

